Brazil ANVISA Regulatory System Framework: The Legal Chain from Lei 6.360/1976 to Lei 9.782/1999

1. Key takeaways

The authorization chain for medical devices in Brazil is held together by two upstream statutes. Lei n° 6.360/1976, published on September 23, 1976, wrote the substantive prohibition into law: nothing may be manufactured, displayed for sale, or delivered for use without registration. Lei n° 9.782/1999, published on January 26, 1999, established the Brazilian Health Regulatory Agency (ANVISA, Agência Nacional de Vigilância Sanitária) to carry the enforcement power, and created the health surveillance fee (TFVS, Taxa de Fiscalização de Vigilância Sanitária) in its Article 23.

GRZAN’s reading is that these two layers are not substitutes: the 1976 law decides whether a company may act at all; the 1999 law decides who supervises and on what funding. Only by reading the chain in this order can a project avoid reducing Brazilian compliance to the single act of submitting a technical dossier.

2. Legal basis

• Basic law on sanitary oversight of health products — Lei n° 6.360/1976, published September 23, 1976, Articles 1, 8, 10, 12 and 82
• Sanitary oversight of trade in drugs, active pharmaceutical ingredients, pharmaceutical excipients and related products — Lei n° 5.991/1973, published December 19, 1973 (DOU Seção 1, p. 13049), Article 4, item IV
• Establishment of the National Health Surveillance Agency and the Brazilian national health surveillance system — Lei n° 9.782/1999, published January 26, 1999, Articles 7, 15 and 23
• Company operating authorization and local sanitary licensing — Decreto n° 8.077/2013, published August 14, 2013, Articles 2, 5 and 7
• Classification, notification and registration of medical devices, and labeling and instruction-for-use requirements — RDC n° 751/2022, resolution of September 15, 2022, Article 4, item VIII, Article 5, Article 60, §1, and Article 66
• Brazilian sanitary violations and penalties law — Lei n° 6.437/1977, signed August 20, 1977, DOU August 24, 1977 (Seção 1, p. 11145), fine range of BRL 2,000–1,500,000

3. Expert insights

The chain follows the sequence of prohibition first, agency second, and GRZAN treats this as the entry point for every Brazilian rule. When Lei n° 6.360/1976 was enacted, Brazil had no independent health surveillance authority; powers were exercised by the Ministry of Health until Lei n° 9.782/1999 transferred them to ANVISA. This order yields two conclusions worth memorizing.

First, the registration precondition sits at statute level, not technical regulation level. ANVISA may use a board resolution (RDC) to detail the procedure, but it cannot relax the statutory ban. Claims that Brazil permits selling first and registering later are misreadings, and the exposure lands directly on the import and distribution stages.

Second, the TFVS is a statutory levy, not an administrative service charge. Its creation and reduction rules live in Article 23 of Lei n° 9.782/1999, while Article 82 of Lei n° 6.360/1976 supplies a separate basis for charging for public services. Being a statutory levy, it cannot be estimated as a bundled price.

Why are devices governed by a 1976 drug law? This is the link GRZAN finds most often missing. Article 1 of Lei n° 6.360/1976 defines the covered objects as drugs, active pharmaceutical ingredients, pharmaceutical excipients and correlatos (related products), pointing directly to Lei n° 5.991/1973. Article 4, item IV of the latter defines a correlato as any substance, product, appliance or accessory (aparelho ou acessório) not covered by the preceding concepts, whose use or application relates to the protection of individual or collective health, personal hygiene or the environment, or diagnostic and analytical purposes, listing optical, medical acoustic, dental and veterinary products. The conclusion: the statutory carrier of a device in Brazilian law is the correlato. There is no Brazilian statute named a medical device law; devices were folded in through the correlato concept. This also explains why secondary material cannot state where Brazilian oversight begins — it searches backward from the RDC layer, while the true starting point lies at the junction of the 1973 and 1976 statutes.

Two further points must be precise. One, the terminology differs across eras: the 1976 law uses the three-term phrase aparelhos, instrumentos e acessórios, while the 1973 law, defining the correlato, uses the two-term aparelho ou acessório; never merge them in citation. Two, this source remains effective: Article 4, items 30 and 35 of RDC n° 751/2022, when defining notification and marketing authorization, cite precisely Article 25, §1 of Lei n° 6.360/1976. GRZAN’s judgment: this is not historical trivia — ANVISA still uses this 1976 drug law to define the two marketing pathways for devices.

The DOU placements of the four statutes serve as verification anchors: Lei n° 5.991/1973 in Seção 1 of December 19, 1973 at page 13049; Lei n° 6.360/1976 in Seção 1 of September 24, 1976 at page 12647; Lei n° 9.782/1999 in Seção 1 of January 27, 1999 at page 1; and Decreto n° 8.077/2013 in Seção 1 of August 15, 2013 at page 18 — the last consistent with its Article 26, under which the decree takes effect upon publication. A one-day gap between signature and DOU publication is common in Brazilian legislation, and this series treats the DOU placement as authoritative. [From primary searches on Planalto and the DOU; not re-checked against consolidated official texts this round, which prevail.]

In project reviews GRZAN has tallied three high-frequency errors: treating the RDC layer as the whole system and overlooking the substantive prohibition at statute level, leaving teams unable to explain the hierarchy during import inspections; confusing company-level and product-level preconditions, assuming that holding the company operating authorization (AFE, Autorização de Funcionamento de Empresa) clears the way for shipment; and booking the TFVS and administrative fines in the same budget line, which makes later self-verification difficult.

A further judgment concerns citation order. At project kickoff, verify top-down: first read what prohibition the statutes impose, then how the decree allocates authorization, and only then ANVISA’s technical provisions. The same order shapes responses and appeals: disputes at the Lei and Decreto level are answered through entity qualification and scope of authorization, while RDC-level technical disputes are answered through validation data and risk argument. Mixing the two levels usually weakens both answers.

4. Practical recommendations

• Make DOU publication a hard shipment gate at initiation: Article 60, §1 of RDC n° 751/2022 bars industrial-scale production, import, display for sale, or delivery for consumption before publication.
• Split the budget into three lines: product registration; AFE and local sanitary licensing (Licença Sanitária / Alvará); and TFVS.
• Write penalty expectations into the risk assessment: fines under Lei n° 6.437/1977 are set by violation severity (leve / grave / gravíssima), with exact amounts governed by current rules [the original amounts in Article 5 of Lei 6.437/1977 were denominated in 1977 cruzeiros, no longer legal tender after repeated currency changes; this series does not list amounts], alongside seizure, sales bans, and cancellation of marketing authorization.
• Prepare technical documentation in Portuguese from initiation: the application form, instructions for use (IFU), and label mock-ups must be in Portuguese.
• Lock the landing structure for foreign entities early: a foreign manufacturer cannot hold the license directly and must connect through a Brazilian legal entity and holder arrangements.
• Maintain an internal regulatory ledger layered by Lei, Decreto, RDC and IN, recording publication and effective dates per entry.
• Archive each approval document with its DOU publication page for retrieval when the license holder changes or ownership transfers.

5. Verification checklist

• □ Confirm the device’s statutory carrier is the correlato of Article 4, item IV of Lei n° 5.991/1973, brought into sanitary oversight via Article 1 of Lei n° 6.360/1976
• □ Confirm the legal origin of the registration precondition is Article 12 of Lei n° 6.360/1976, not merely one RDC
• □ Confirm ANVISA’s powers and TFVS creation rest on Articles 7, 15 and 23 of Lei n° 9.782/1999
• □ Confirm AFE and the Licença Sanitária form a separate, parallel set of preconditions (Articles 2 and 7 of Decreto n° 8.077/2013)
• □ Check the current consolidated version of RDC n° 751/2022 and its repeal list in Article 66
• □ Ensure the project budget lists TFVS separately, estimated per application matter

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides registration and compliance support for medical device and IVD manufacturers entering the Brazilian market, covering ANVISA pathway strategy, classification and dossier preparation, BGMP and CBPF coordination, TFVS budgeting, and post-market compliance. For assistance with Brazilian regulatory requirements, contact info@grzanglobal.com.